Why the study?
Does losartan or captopril reduce splenic T cell activation and inflammation in a murine model of cerebral malaria?
Population
C57BL/6 mice (8-12 weeks old) infected with Plasmodium berghei ANKA (rodent model of cerebral malaria).
Comparison
Losartan or captopril administered by gavage for… vs Vehicle-treated infected mice and naive control…
Design
Preclinical
Follow-up
Up to 10 days
Key result
Treatment with losartan or captopril reduced infection-induced T cell activation to control levels and diminished IFN-gamma and IL-17 production by CD4+ T cells by 67% and 70%, respectively.
Authors
Loading...
Does not support clinical use in malaria; hypothesis-generating for AT1 blockade in human cerebral malaria.
Does losartan or captopril reduce splenic T cell activation and inflammation in a murine model of cerebral malaria?
p-value: p=<0.05
Angiotensin II blockade with losartan or captopril reduces splenic T cell activation and inflammatory cytokine production in a murine model of cerebral malaria, suggesting a role for the AT1/Ang II axis in malaria pathogenesis.
Silva‐Filho et al. (2013) studied Plasmodium berghei ANKA infection (cerebral malaria model). Losartan or Captopril vs. Vehicle was evaluated on T cell activation (CD69 expression) and cytokine production (IFN-gamma and IL-17) (p=<0.05). Treatment with losartan or captopril reduced infection-induced T cell activation to control levels and diminished IFN-gamma and IL-17 production by CD4+ T cells by 67% and 70%, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: